Real-time insights. Smarter decisions. Better trades.
🔍 Search Stocks 14 day Free Trial
POLYNOVO LIMITED (PNV)ASX AI Signals has generated 1 signal(s) for PNV during the last 90 days, indicating Moderate trading activity
Latest PNV Signals | |
| 15/05/2026 | BUY |
| 17/03/2026 | NEUTRAL |
| 16/03/2026 | NEUTRAL |
PNV Share Price | |
| Current Price | $0.980 |
| 52 Week High | $1.625 |
| 52 Week Low: | $0.875 |
| Trading at (% of 52 Week High) | 60.31% |
Polynovo Limited (ASX: PNV) is a medical device company that develops and commercializes innovative wound care products, including its proprietary NovoSorb biodegradable polymer technology. The company primarily focuses on treating chronic wounds, burns, and surgical wounds through its advanced dermal regeneration scaffolds. Polynovo operates internationally, supplying its products to healthcare providers worldwide.
The Health Care Equipment & Services sector on the ASX includes companies that produce medical devices, equipment, and supplies, as well as those providing healthcare-related services. This sector covers a wide range of products such as surgical instruments, diagnostic machines, and health monitoring devices. It also includes businesses involved in healthcare management, medical laboratories, and support services. These companies play a key role in supporting hospitals, clinics, and other healthcare providers to improve patient care. The sector is influenced by factors like technological advances, regulatory changes, and demand for healthcare services.
The BUY signal for POLYNOVO LIMITED (PNV) is supported by positive momentum and potential growth in the medical technology sector. However, the relatively low stock price and market volatility introduce moderate risk, warranting a cautious approach.
PolyNovo (ASX:PNV) has appointed Robert Douglas to its Board of Directors, a move that brings decades of international medical device leadership into the mix. Investors are tuning in to see what his experience could mean for PolyNovo’s strategic direction.
See our latest analysis for PolyNovo.
Pol PolyNovo Limited recently appointed Mr. Robert Douglas to its Board of Directors, bringing over thirty-five years of experience in medical device technology, digital health, and public company governance, with senior leadership roles at ResMed and board responsibilities at Globus Medical. This appoi While PolyNovo Limited (ASX:PNV) might not have the largest market cap around , it saw a significant share price rise of 55% in the past couple of months on the ASX. The recent rally in share prices has nudged the company in the right direction, though it still falls short of its yearly peak. As a s Key Insights
Using the 2 Stage Free Cash Flow to Equity, PolyNovo fair value estimate is AU$2.95 Current share price of AU$1.55 suggests PolyNovo is potentially 48% undervalued The AU$1.81 analyst price target for PNV is 39% less than our estimate of fair value
Does the December share price for Po When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose your money. But when you pick a company that is really flourishing, you can make more than 100%. One great example is PolyNovo Limited (ASX:PNV) which saw its share price drive 162% hiLatest POLYNOVO LIMITED(PNV) News
PolyNovo (ASX:PNV): Valuation Perspectives Following Board Appointment of ResMed Veteran Robert Douglas
Will PolyNovo’s (ASX:PNV) New Board Addition Shape Its U.S. Medtech Strategy?
Is PolyNovo Limited (ASX:PNV) Potentially Undervalued?
PolyNovo Limited (ASX:PNV) Shares Could Be 48% Below Their Intrinsic Value Estimate
PolyNovo (ASX:PNV) shareholders have earned a 21% CAGR over the last five years
Get access to daily BUY & SELL signals, advanced AI analysis, watchlists and email alerts.
14 Day Free Trial • Cancel Anytime • Founders Price $15/month
Start My Free Trial